Pancreatic Cancer Trial, Recruiting NCT05746182 Sponsor: University of California, San Francisco Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Pancreatic Cancer Trial, Recruiting

NCT05746182
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older who have been diagnosed with a pancreatic neuroendocrine neoplasm (a type of tumour in the pancreas), confirmed by a tissue sample taken from any location in the body, such as the original tumour site or a spread (metastatic) site.
  • Both newly diagnosed and previously diagnosed cases are eligible, regardless of the grade or stage of the condition.
  • People who are willing and able to follow the study procedures throughout the trial.

Who may not be able to join:

  • People who are unable to give informed consent to participate in the study.
  • For people who have not previously had a broad genetic (germline) test covering at least 80 genes, the following additional restrictions apply:
  • People who cannot speak or read one of the languages supported by the genetic testing station — currently English, Korean, Japanese, Vietnamese, Russian, Tagalog, Farsi, Spanish, Cantonese, Mandarin, or Arabic (confirm with trial site if your language is not listed).
  • People who currently have an active blood cancer (such as leukaemia or lymphoma).
  • People who have previously had a bone marrow or stem cell transplant from another person.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Emily Bergsland, MD, University of California, San Francisco

Phone: (415) 502-6313

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
7 April 2023
Est. completion
31 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Rate of overall pathogenic germline mutations

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov